GAMMA Investing LLC Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

GAMMA Investing LLC increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4,682.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,845 shares of the biotechnology company's stock after buying an additional 39,991 shares during the quarter. GAMMA Investing LLC's holdings in Sarepta Therapeutics were worth $2,607,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SRPT. Louisiana State Employees Retirement System lifted its position in shares of Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock worth $3,222,000 after buying an additional 100 shares in the last quarter. EP Wealth Advisors LLC grew its position in shares of Sarepta Therapeutics by 2.2% in the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after purchasing an additional 105 shares in the last quarter. Manchester Capital Management LLC increased its position in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the period. CIBC Asset Management Inc increased its holdings in Sarepta Therapeutics by 5.1% during the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after acquiring an additional 139 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in shares of Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock worth $352,000 after buying an additional 145 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on SRPT shares. Scotiabank upgraded shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 target price for the company in a research report on Friday, June 6th. Needham & Company LLC cut their price target on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. JPMorgan Chase & Co. decreased their target price on Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating for the company in a report on Tuesday, May 20th. HC Wainwright restated a "neutral" rating and issued a $40.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, May 22nd. Finally, Wells Fargo & Company dropped their target price on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $122.61.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $1.13 on Friday, reaching $36.18. 3,189,461 shares of the stock were exchanged, compared to its average volume of 1,808,292. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a one year low of $34.10 and a one year high of $173.25. The firm has a market capitalization of $3.56 billion, a PE ratio of 28.94 and a beta of 0.61. The company's 50-day simple moving average is $46.51 and its two-hundred day simple moving average is $87.40.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter last year, the firm posted $0.73 EPS. The firm's quarterly revenue was up 80.2% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.